论文部分内容阅读
C型凝集素9家族A成员(CLEC9A),又称为树突状细胞-NK细胞凝集素群受体1(DNGR-1),属于非经典的2型跨膜C型凝集素样受体,其表达具有高度的树突状细胞(DC)限制性。小鼠CLEC9A主要表达在CD8α~+DC和CD103~+DC表面,人CLEC9A主要表达在血液树突状细胞抗原3阳性DC(BDCA3~+DC)表面。在表型和功能方面,人的同时表达CLEC9A和BDCA3(CLEC9A~+BDCA3~+)的DC与小鼠的CD8α~+DC具有相似性。CLEC9A能够与坏死或受损细胞的纤维状肌动蛋白结合,经细胞质区的免疫受体酪氨酸活化基序结构启动细胞内信号的转导。CLEC9A能介导内吞作用,参与交叉提呈抗原等作用,在抗病毒感染、肿瘤预防与治疗和疫苗的研究中具有潜在的应用前景。本文阐述了CLEC9A分子的研究进展。
C-type lectin 9 family member A (CLEC9A), also known as dendritic cell-NK cell lectin receptor 1 (DNGR-1), is a non-classical type 2 transmembrane C-type lectin- Its expression is highly dendritic (DC) -deficient. Mouse CLEC9A is mainly expressed on the surface of CD8α ~ + DC and CD103 ~ + DC, and human CLEC9A is mainly expressed on the surface of blood DC-positive DCs (BDCA3 ~ + DC). In terms of phenotype and function, human DCs expressing CLEC9A and BDCA3 (CLEC9A ~ + BDCA3 ~ +) have similarities with CD8α ~ + DCs in mice. CLEC9A is capable of binding to the fibrillar actin of necrotic or damaged cells and initiates the transduction of intracellular signals via the immunoreceptor tyrosine-activated motif structure of the cytoplasmic domain. CLEC9A can mediate endocytosis, participate in the role of cross-presentation of antigens and other potential applications in the study of antiviral infections, cancer prevention and treatment and vaccines. This article describes the research progress of CLEC9A molecules.